|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
CN105755044A
(zh)
|
2011-04-22 |
2016-07-13 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体及其使用方法
|
|
TWI698240B
(zh)
|
2012-05-15 |
2020-07-11 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
EP3031921B1
(en)
|
2012-12-12 |
2025-03-12 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
US10266845B2
(en)
*
|
2013-02-08 |
2019-04-23 |
The Trustees Of The University Of Pennsylvania |
Enhanced AAV-mediated gene transfer for retinal therapies
|
|
US9567376B2
(en)
|
2013-02-08 |
2017-02-14 |
The Trustees Of The University Of Pennsylvania |
Enhanced AAV-mediated gene transfer for retinal therapies
|
|
AU2014235096B2
(en)
|
2013-03-15 |
2020-03-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating MPSI
|
|
CN105764531A
(zh)
|
2013-05-16 |
2016-07-13 |
应用遗传科技公司 |
用于治疗色盲和其它疾病的启动子、表达盒、载体、药盒和方法
|
|
EP3003391B1
(en)
|
2013-05-31 |
2021-09-22 |
The Regents of The University of California |
Adeno-associated virus variants and methods of use thereof
|
|
CN105492611A
(zh)
|
2013-06-17 |
2016-04-13 |
布罗德研究所有限公司 |
用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
|
|
WO2014204724A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
RU2716420C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
|
|
MX374532B
(es)
|
2013-06-17 |
2025-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
|
|
WO2014207190A1
(en)
*
|
2013-06-28 |
2014-12-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for expressing a polynucleotide of interest in the retina of a subject
|
|
EP3019610B2
(en)
|
2013-07-08 |
2025-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof
|
|
ES2739288T3
(es)
|
2013-09-13 |
2020-01-30 |
California Inst Of Techn |
Recuperación selectiva
|
|
JP6712948B2
(ja)
|
2013-12-12 |
2020-06-24 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
|
|
JP7103750B2
(ja)
*
|
2013-12-12 |
2022-07-20 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
SG10201804975PA
(en)
|
2013-12-12 |
2018-07-30 |
Broad Inst Inc |
Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
US20170007720A1
(en)
*
|
2014-02-21 |
2017-01-12 |
University Of Florida Research Foundation, Inc. |
Methods and compositions for gene delivery to on bipolar cells
|
|
EP3113787B1
(en)
*
|
2014-03-04 |
2019-12-04 |
University of Florida Research Foundation, Inc. |
Improved raav vectors and methods for transduction of photoreceptors and rpe cells
|
|
US11028388B2
(en)
|
2014-03-05 |
2021-06-08 |
Editas Medicine, Inc. |
CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
|
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
ES2745769T3
(es)
|
2014-03-10 |
2020-03-03 |
Editas Medicine Inc |
Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10)
|
|
EP4678754A3
(en)
*
|
2014-03-11 |
2026-04-08 |
Wayne State University |
A modified mglur6 promoter and methods of use
|
|
EP3800191B1
(en)
|
2014-03-17 |
2025-08-20 |
Adverum Biotechnologies, Inc. |
Compositions and methods for enhanced gene expression in cone cells
|
|
EP3122880B1
(en)
|
2014-03-26 |
2021-05-05 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
|
EP3540061A1
(en)
|
2014-04-02 |
2019-09-18 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating primary open angle glaucoma
|
|
LT3137497T
(lt)
|
2014-05-02 |
2021-07-26 |
Genzyme Corporation |
Aav vektoriai, skirti tinklainės ir cns genų terapijai
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
EP3188762A4
(en)
*
|
2014-07-31 |
2018-01-10 |
The Board of Regents of the University of Oklahoma |
High isomerohydrolase activity mutants of mammalian rpe65
|
|
SG11201702055PA
(en)
*
|
2014-09-16 |
2017-04-27 |
Genzyme Corp |
Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
|
|
RU2716991C2
(ru)
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
Полинуклеотиды aadc для лечения болезни паркинсона
|
|
KR20230145206A
(ko)
|
2014-11-14 |
2023-10-17 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
WO2016077687A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
EP3256170B1
(en)
*
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
WO2016133917A1
(en)
|
2015-02-16 |
2016-08-25 |
University Of Florida Research Foundation |
Raav vector compositions, methods for targeting vascular endothelial cells and use in treatment of type i diabetes
|
|
AU2016219789B2
(en)
*
|
2015-02-20 |
2021-03-25 |
Fondazione Telethon |
Methods and compositions for treating genetic eye diseases
|
|
US11021519B2
(en)
*
|
2015-03-02 |
2021-06-01 |
Adverum Biotechnologies, Inc. |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
|
JP6836999B2
(ja)
|
2015-03-24 |
2021-03-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ |
アデノ随伴ウイルス変異体及びその使用方法
|
|
US10081659B2
(en)
|
2015-04-06 |
2018-09-25 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Adeno-associated vectors for enhanced transduction and reduced immunogenicity
|
|
JP2018522249A
(ja)
|
2015-04-24 |
2018-08-09 |
エディタス・メディシン、インコーポレイテッド |
Ｃａｓ９分子／ガイドｒｎａ分子複合体の評価
|
|
WO2016183585A1
(en)
*
|
2015-05-14 |
2016-11-17 |
Joslin Diabetes Center, Inc. |
Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
|
|
TWI906646B
(zh)
|
2015-06-18 |
2025-12-01 |
美商博得學院股份有限公司 |
降低脫靶效應的ｃｒｉｓｐｒ酶突變
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
WO2017093566A1
(en)
*
|
2015-12-04 |
2017-06-08 |
Universite Pierre Et Marie Curie (Paris 6) |
Promoters and uses thereof
|
|
KR102423442B1
(ko)
*
|
2015-12-11 |
2022-07-20 |
캘리포니아 인스티튜트 오브 테크놀로지 |
아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
|
|
WO2017099838A1
(en)
|
2015-12-11 |
2017-06-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Gene therapy for combined methylmalonic acidemia/aciduria and hyperhomocysteinemia/homocystinuria, cobalamin c type, and deficiency of mmachc
|
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
|
CA3012195A1
(en)
|
2016-02-03 |
2017-08-10 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
|
US11512311B2
(en)
|
2016-03-25 |
2022-11-29 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
|
|
SG11201808426XA
(en)
|
2016-04-15 |
2018-10-30 |
Univ Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
WO2017187272A1
(en)
|
2016-04-29 |
2017-11-02 |
Gensight Biologics Sa |
Optogenetic visual restoration using chrimson
|
|
AU2017257169B2
(en)
|
2016-04-29 |
2021-07-08 |
Adverum Biotechnologies, Inc. |
Evasion of neutralizing antibodies by a recombinant adeno-associated virus
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
US11866462B2
(en)
|
2016-05-04 |
2024-01-09 |
Oregon Health & Science University |
Recombinant adeno-associated viral vectors
|
|
US11364308B2
(en)
|
2016-05-13 |
2022-06-21 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
|
KR20240056729A
(ko)
|
2016-05-18 |
2024-04-30 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
KR102427379B1
(ko)
|
2016-05-18 |
2022-08-02 |
보이저 테라퓨틱스, 인크. |
헌팅톤 질환을 치료하기 위한 조성물 및 방법
|
|
MA44546B1
(fr)
*
|
2016-06-15 |
2021-03-31 |
Univ California |
Virus adéno-associés variants et procédés d'utilisation
|
|
KR20190038536A
(ko)
*
|
2016-06-16 |
2019-04-08 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
안구 혈관신생을 저하시키기 위한 조성물 및 방법
|
|
ES2840059T3
(es)
*
|
2016-06-16 |
2021-07-06 |
Adverum Biotechnologies Inc |
Tratamiento de la DMRE mediante el uso de la variante AAV2 con aflibercept
|
|
AU2017302013B2
(en)
*
|
2016-07-29 |
2022-05-26 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
BR112019001887A2
(pt)
|
2016-08-02 |
2019-07-09 |
Editas Medicine Inc |
composições e métodos para o tratamento de doença associada a cep290
|
|
EP3504227A1
(en)
|
2016-08-29 |
2019-07-03 |
Wayne State University |
Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
|
|
WO2018044933A1
(en)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
CA3040179A1
(en)
*
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
|
JP6779546B2
(ja)
*
|
2016-11-06 |
2020-11-04 |
ナノスコープ テクノロジーズ エルエルシーＮａｎｏｓｃｏｐｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｌｃ |
視力回復のための多特性オプシンによる光遺伝学的調節及びその別の用途
|
|
US11236360B2
(en)
|
2016-12-09 |
2022-02-01 |
Regents Of The University Of Minnesota |
Adeno-associated viruses engineered for selectable tropism
|
|
KR20250022877A
(ko)
|
2017-01-31 |
2025-02-17 |
리젠엑스바이오 인크. |
완전히-인간 글리코실화된 인간 알파-l-이두로니다아제(idua)를 이용한 뮤코다당증 1형의 치료
|
|
JP2020510424A
(ja)
*
|
2017-02-28 |
2020-04-09 |
アドヴェラム バイオテクノロジーズ， インコーポレイテッド |
改変ａａｖカプシドおよびその使用
|
|
WO2018170184A1
(en)
|
2017-03-14 |
2018-09-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
EP4653536A3
(en)
|
2017-03-17 |
2026-02-25 |
Adverum Biotechnologies, Inc. |
Compositions and methods for enhanced gene expression
|
|
EP3609542B1
(en)
*
|
2017-04-11 |
2023-02-22 |
Ruprecht-Karls-Universität Heidelberg |
Adeno-associated virus library
|
|
KR20190139951A
(ko)
|
2017-04-14 |
2019-12-18 |
리젠엑스바이오 인크. |
인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
|
|
JP2020518258A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
|
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
EP3622070A2
(en)
|
2017-05-10 |
2020-03-18 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
CA3053154A1
(en)
*
|
2017-06-30 |
2019-01-03 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsids and methods of use thereof
|
|
CA3068328A1
(en)
|
2017-07-06 |
2019-01-10 |
The Trustees Of The University Of Pennsylvania |
Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
|
|
CA3070087A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
|
JP2020534788A
(ja)
|
2017-08-28 |
2020-12-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
アデノ随伴ウイルスカプシド変異体及びその使用方法
|
|
RU2770922C2
(ru)
|
2017-09-20 |
2022-04-25 |
4Д Молекьюлар Терапьютикс Инк. |
Капсиды вариантов аденоассоциированных вирусов и методы их применения
|
|
AU2018338728B2
(en)
|
2017-09-29 |
2025-01-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
|
|
US12043848B2
(en)
|
2017-10-16 |
2024-07-23 |
Vigeneron Gmbh |
AAV vectors
|
|
EP3697908A1
(en)
|
2017-10-16 |
2020-08-26 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
MX2020003888A
(es)
|
2017-10-18 |
2020-11-06 |
Regenxbio Inc |
Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
|
|
AU2018350990A1
(en)
|
2017-10-18 |
2020-05-21 |
Regenxbio Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
|
|
CN111867635A
(zh)
*
|
2017-10-20 |
2020-10-30 |
法国国家卫生及研究医学协会 |
包括视网膜下递送治疗有效量的重组aav9衍生载体的在对象的视锥细胞光感受器中表达目的多核苷酸的方法
|
|
WO2019084015A1
(en)
*
|
2017-10-23 |
2019-05-02 |
Daniel Schmidt |
PROGRAMMABLE SET OF VIRUS COMPOSITES FOR ADMINISTRATION OF GENES TARGETING A RECEPTOR
|
|
CN111770999A
(zh)
|
2017-11-27 |
2020-10-13 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和用于抑制血管生成的应用
|
|
US20190256867A1
(en)
|
2018-02-01 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
CN111712566A
(zh)
|
2018-02-08 |
2020-09-25 |
应用干细胞有限公司 |
用于筛选靶基因变体的方法
|
|
JP7244547B2
(ja)
|
2018-02-19 |
2023-03-22 |
ホモロジー・メディシンズ・インコーポレイテッド |
Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
|
|
US12558434B2
(en)
|
2018-02-20 |
2026-02-24 |
The Trustees Of The University Of Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
|
KR102907245B1
(ko)
|
2018-03-14 |
2026-01-05 |
에디타스 메디신, 인코포레이티드 |
혈색소병증 치료를 위한 시스템 및 방법
|
|
MX2020010465A
(es)
*
|
2018-04-03 |
2021-01-08 |
|
Vectores de virus para direccionamiento a tejidos oftalmicos.
|
|
WO2019212922A1
(en)
|
2018-04-29 |
2019-11-07 |
Regenxbio Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
|
CA3098565A1
(en)
|
2018-04-29 |
2019-11-07 |
Claire G. ZHANG |
Scalable clarification process for recombinant aav production
|
|
CA3100006A1
(en)
*
|
2018-05-11 |
2019-11-14 |
Massachusetts Eye And Ear Infirmary |
Altering tissue tropism of adeno-associated viruses
|
|
US11821009B2
(en)
|
2018-05-15 |
2023-11-21 |
Cornell University |
Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
|
|
KR20210019996A
(ko)
|
2018-05-15 |
2021-02-23 |
보이저 테라퓨틱스, 인크. |
파킨슨병의 치료를 위한 조성물 및 방법
|
|
US12070702B2
(en)
|
2018-06-14 |
2024-08-27 |
Regenxbio Inc. |
Anion exchange chromatography for recombinant AAV production
|
|
EP3808840A4
(en)
*
|
2018-06-14 |
2022-03-23 |
Avixgen Inc. |
Pharmaceutical composition comprising fusion protein of cell-penetrating peptide and rpe65 for treatment of leber's congenital amaurosis
|
|
WO2020014471A1
(en)
|
2018-07-11 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for delivery of agents across the blood-brain barrier
|
|
EP3833745A1
(en)
|
2018-08-10 |
2021-06-16 |
REGENXBIO Inc. |
Scalable method for recombinant aav production
|
|
CN113966399A
(zh)
|
2018-09-26 |
2022-01-21 |
加州理工学院 |
用于靶向基因疗法的腺相关病毒组合物
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
BR112021006052A2
(pt)
|
2018-10-01 |
2021-09-08 |
Ultragenyx Pharmaceutical Inc. |
Terapia gênica para tratar acidemia propiônica
|
|
CN113166208B
(zh)
|
2018-10-02 |
2024-11-22 |
沃雅戈治疗公司 |
重新定向aav衣壳的嗜性
|
|
CN112912518A
(zh)
|
2018-10-15 |
2021-06-04 |
再生生物股份有限公司 |
用于测量复制缺陷型病毒载体和病毒的感染性的方法
|
|
KR20220022107A
(ko)
*
|
2018-12-05 |
2022-02-24 |
아베오나 테라퓨틱스 인코퍼레이티드 |
유전자 전달을 위한 재조합 아데노-연관 바이러스 벡터
|
|
US20200193156A1
(en)
|
2018-12-12 |
2020-06-18 |
Tesseract Health, Inc. |
Biometric identification techniques
|
|
EP3897679A1
(en)
|
2018-12-21 |
2021-10-27 |
Wade Wei-De Chien |
Adeno-associated viruses and their uses for inner ear therapy
|
|
CN110437317B
(zh)
*
|
2019-01-30 |
2023-05-02 |
上海科技大学 |
具有变异衣壳蛋白的腺相关病毒及其用途
|
|
CN113728108A
(zh)
|
2019-02-15 |
2021-11-30 |
桑格摩生物治疗股份有限公司 |
用于生产重组aav的组合物和方法
|
|
SG11202108044YA
(en)
|
2019-02-25 |
2021-09-29 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
US20220154211A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
CN111621502B
(zh)
*
|
2019-02-28 |
2023-05-02 |
武汉纽福斯生物科技有限公司 |
视网膜劈裂蛋白的编码序列、其表达载体构建及其应用
|
|
US20220047618A1
(en)
|
2019-02-28 |
2022-02-17 |
Regeneron Pharmaceuticals, Inc. |
Adeno-associated virus vectors for the delivery of therapeutics
|
|
JP7597380B2
(ja)
|
2019-03-04 |
2024-12-10 |
アドヴェラム バイオテクノロジーズ， インコーポレイテッド |
対側眼へのａａｖ遺伝子治療の逐次的硝子体内投与
|
|
EP3715358A1
(en)
*
|
2019-03-28 |
2020-09-30 |
Universität zu Köln |
Mutated adeno-associated virus capsid proteins, aav particle comprising the same and liver directed aav vector gene therapy
|
|
EP3947700A4
(en)
|
2019-04-01 |
2023-01-04 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
WO2020206098A1
(en)
|
2019-04-03 |
2020-10-08 |
Regenxbio Inc. |
Gene therapy for eye pathologies
|
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
FI3953483T3
(fi)
|
2019-04-11 |
2023-11-30 |
Regenxbio Inc |
Kokoekskluusiokromatografiamenetelmiä rekombinanttien adenoassosioituneiden viruskoostumusten karakterisoimiseksi
|
|
TW202332458A
(zh)
|
2019-04-19 |
2023-08-16 |
美商銳進科斯生物股份有限公司 |
腺相關病毒載體調配物及方法
|
|
WO2020219868A1
(en)
|
2019-04-24 |
2020-10-29 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
|
KR102917057B1
(ko)
|
2019-04-24 |
2026-01-23 |
다카라 바이오 가부시키가이샤 |
뇌에 지향성을 가지는 aav 돌연변이체
|
|
TW202532428A
(zh)
*
|
2019-04-26 |
2025-08-16 |
美商愛德維仁生物科技公司 |
用於玻璃體內遞送之變異體aav蛋白殼
|
|
EP3752524A4
(en)
*
|
2019-04-27 |
2021-11-24 |
Ocugen, Inc. |
ADENO-ASSOCIATED VIRUS VECTOR MEDIATED GENE THERAPY FOR OPHTHALMIC DISEASE
|
|
US11737665B2
(en)
|
2019-06-21 |
2023-08-29 |
Tesseract Health, Inc. |
Multi-modal eye imaging with shared optical path
|
|
CA3144986A1
(en)
*
|
2019-06-27 |
2020-12-30 |
University Of Florida Research Foundation, Incorporated |
Enhancing aav-mediated transduction of ocular tissues with hyaluronic acid
|
|
EP3997225A1
(en)
|
2019-07-10 |
2022-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
|
EP3997214B1
(en)
*
|
2019-07-11 |
2023-08-02 |
Centre National de la Recherche Scientifique |
Chemically-modified adeno-associated virus
|
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
|
EP4004214A1
(en)
|
2019-07-26 |
2022-06-01 |
RegenxBio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
|
RU2751592C2
(ru)
|
2019-08-22 |
2021-07-15 |
Общество С Ограниченной Ответственностью "Анабион" |
Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
|
|
CN114502197A
(zh)
|
2019-08-26 |
2022-05-13 |
再生生物股份有限公司 |
用全人经翻译后修饰的抗VEGF Fab治疗糖尿病性视网膜病变
|
|
CA3153972A1
(en)
|
2019-09-09 |
2021-03-18 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modulating the interaction between adeno-associated virus (aav) and the aav receptor (aavr) for altered bio-distribution of aav
|
|
HRP20260137T1
(hr)
|
2019-09-11 |
2026-03-13 |
Adverum Biotechnologies, Inc. |
Liječenje očnih neovaskularnih bolesti upotrebom aav2 varijanti koje kodiraju aflibercept
|
|
EP4028064A1
(en)
*
|
2019-09-12 |
2022-07-20 |
The Broad Institute, Inc. |
Engineered adeno-associated virus capsids
|
|
GB201913974D0
(en)
|
2019-09-27 |
2019-11-13 |
King S College London |
Vector
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
WO2021071835A1
(en)
|
2019-10-07 |
2021-04-15 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
|
AU2020368539A1
(en)
|
2019-10-16 |
2022-04-28 |
Massachusetts Institute Of Technology |
Engineered muscle targeting compositions
|
|
CN118221785A
(zh)
*
|
2019-10-16 |
2024-06-21 |
上海药明康德新药开发有限公司 |
新的aav变体
|
|
CN114729009A
(zh)
*
|
2019-10-31 |
2022-07-08 |
伯尔尼大学 |
用于眼部基因递送的aav载体变体
|
|
US12521451B2
(en)
*
|
2019-11-08 |
2026-01-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
|
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
|
WO2021108530A1
(en)
*
|
2019-11-26 |
2021-06-03 |
University Of Massachusetts |
Recombinant adeno-associated virus for delivery of kh902 (conbercept) and uses thereof
|
|
TWI908746B
(zh)
|
2019-11-28 |
2025-12-21 |
美商銳進科斯生物股份有限公司 |
微小肌縮蛋白基因療法之構築體及其用途
|
|
CN115279400B
(zh)
|
2020-01-10 |
2026-04-28 |
布里格姆妇女医院 |
用于跨血脑屏障递送免疫治疗剂以治疗脑癌的方法和组合物
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
KR20220131522A
(ko)
|
2020-01-22 |
2022-09-28 |
리젠엑스바이오 인크. |
완전-인간 글리코실화된 인간 알파-l-이두로니다아제 (idua)를 사용한 점액다당류증 i의 치료
|
|
WO2023172491A1
(en)
|
2022-03-07 |
2023-09-14 |
Ultragenyx Pharmaceutical Inc. |
Modified batch aav production systems and methods
|
|
CA3168251A1
(en)
|
2020-01-29 |
2021-08-05 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis iva
|
|
BR112022015183A2
(pt)
|
2020-01-29 |
2022-12-20 |
Regenxbio Inc |
Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
|
|
JP2023514204A
(ja)
|
2020-02-14 |
2023-04-05 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
Ｃｄｋｌ５欠損障害を処置するための遺伝子治療
|
|
US20230235353A1
(en)
|
2020-03-19 |
2023-07-27 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
|
WO2021202532A1
(en)
|
2020-03-31 |
2021-10-07 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
|
US20230159609A1
(en)
*
|
2020-04-10 |
2023-05-25 |
Sorbonne Université |
G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
|
|
US12552838B2
(en)
|
2020-04-20 |
2026-02-17 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
CA3179895A1
(en)
|
2020-04-24 |
2021-10-28 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for preventing induction of immune responses to the transduced cells expressing a transgene product after ocular gene therapy
|
|
EP4103211A4
(en)
|
2020-04-27 |
2023-08-23 |
4D Molecular Therapeutics Inc. |
CODON-OPTIMISED GLA GENES AND THEIR USES
|
|
TWI900553B
(zh)
|
2020-05-13 |
2025-10-11 |
美商航海家醫療公司 |
Aav蛋白殼之趨性重定向
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
US12031147B2
(en)
|
2020-05-29 |
2024-07-09 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsids and methods of use thereof
|
|
KR20230050336A
(ko)
|
2020-07-10 |
2023-04-14 |
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) |
뇌전증을 치료하기 위한 방법과 조성물
|
|
CN112226461B
(zh)
*
|
2020-08-21 |
2022-04-22 |
华侨大学 |
Cd4阳性细胞特异性基因传递载体及其应用
|
|
AU2021329527A1
(en)
*
|
2020-08-21 |
2023-03-23 |
Capsida, Inc. |
Adeno-associated virus compositions having preferred expression levels
|
|
US12129287B2
(en)
|
2020-09-14 |
2024-10-29 |
President And Fellows Of Harvard College |
Recombinant adeno associated virus encoding clarin-1 and uses thereof
|
|
WO2022060916A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
WO2022060915A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
|
CN113754727B
(zh)
*
|
2020-09-30 |
2022-07-12 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
KR20230106598A
(ko)
|
2020-10-07 |
2023-07-13 |
리젠엑스바이오 인크. |
겔 제형과 같은 맥락막위 투여용 제형
|
|
MX2023003699A
(es)
|
2020-10-07 |
2023-04-21 |
Regenxbio Inc |
Virus adenoasociados para el suministro ocular de genoterapia.
|
|
CA3198372A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as high viscosity formulations
|
|
CA3198368A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
BR112023006305A2
(pt)
|
2020-10-09 |
2023-05-09 |
Tenaya Therapeutics Inc |
Métodos e composições de terapia gênica com placofilina-2
|
|
CA3195967A1
(en)
|
2020-10-28 |
2022-05-05 |
Xu Wang |
Vectorized anti-tnf-? antibodies for ocular indications
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
AU2021369833A1
(en)
|
2020-10-29 |
2023-06-08 |
Regenxbio Inc. |
Vectorized tnf-alpha antagonists for ocular indications
|
|
US20230390418A1
(en)
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
JP2023550548A
(ja)
*
|
2020-11-10 |
2023-12-01 |
アビラマックス・バイオファーマ・インコーポレイテッド |
操作されたウイルスカプシドおよび使用方法
|
|
WO2022120022A1
(en)
|
2020-12-02 |
2022-06-09 |
Regeneron Pharmaceuticals, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
|
EP4263575A4
(en)
*
|
2020-12-16 |
2025-05-07 |
Children's Medical Research Institute |
Adeno-associated virus capsids and vectors
|
|
EP4263841A1
(en)
|
2020-12-16 |
2023-10-25 |
REGENXBIO Inc. |
Method of producing a recombinant adeno-associated virus particle
|
|
TW202241943A
(zh)
|
2020-12-29 |
2022-11-01 |
美商銳進科斯生物股份有限公司 |
Tau特異性抗體基因療法組合物、方法及其用途
|
|
JP2024503895A
(ja)
|
2021-01-21 |
2024-01-29 |
リジェネクスバイオ インコーポレイテッド |
組換えポリペプチド及びウイルスの生成の改善
|
|
EP4291249A2
(en)
|
2021-02-10 |
2023-12-20 |
RegenxBio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
|
|
CN113121652B
(zh)
*
|
2021-04-19 |
2022-10-11 |
上海信致医药科技有限公司 |
视网膜和肌肉高亲和性腺相关病毒衣壳蛋白及相关应用
|
|
CN113121651B
(zh)
*
|
2021-04-19 |
2023-11-17 |
信念医药科技(上海)有限公司 |
低中和抗体腺相关病毒衣壳蛋白
|
|
WO2022223644A2
(en)
|
2021-04-20 |
2022-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for treating retinal degenerative disorders
|
|
JP2024517143A
(ja)
|
2021-04-26 |
2024-04-19 |
リジェネックスバイオ インコーポレイテッド |
ジストロフィン異常症の治療のためのマイクロジストロフィン遺伝子療法投与
|
|
BR112023019056A2
(pt)
|
2021-04-27 |
2024-01-16 |
Adverum Biotechnologies Inc |
Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte
|
|
US20240218397A1
(en)
|
2021-05-04 |
2024-07-04 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
|
EP4337267A1
(en)
|
2021-05-11 |
2024-03-20 |
RegenxBio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
|
CA3221439A1
(en)
|
2021-05-26 |
2022-12-01 |
Sparingvision |
G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
|
|
US20240252679A1
(en)
*
|
2021-05-28 |
2024-08-01 |
Shanghai Regenelead Therapies Co., Ltd. |
Recombinant adeno-associated virus having variant capsid, and application thereof
|
|
EP4346767A4
(en)
*
|
2021-06-03 |
2025-06-25 |
Dyno Therapeutics, Inc. |
CAPSIDE VARIANTS AND METHODS OF USE THEREOF
|
|
US20250276088A1
(en)
|
2021-07-07 |
2025-09-04 |
Institut National de la Santé et de la Recherche Médicale |
Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathies
|
|
KR20240032971A
(ko)
|
2021-07-08 |
2024-03-12 |
테나야 테라퓨틱스, 인코포레이티드 |
유전자 요법을 위한 최적화된 발현 카세트
|
|
US20240409955A1
(en)
|
2021-07-19 |
2024-12-12 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
|
US20250019721A1
(en)
|
2021-08-11 |
2025-01-16 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for treating a muscular dystrophy
|
|
AR126839A1
(es)
|
2021-08-20 |
2023-11-22 |
Llc «Anabion» |
Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta
|
|
CR20240137A
(es)
|
2021-08-20 |
2024-07-29 |
Biocad Joint Stock Co |
Método para obtener una cápside de virus adenoasociado modificada
|
|
AR126840A1
(es)
|
2021-08-20 |
2023-11-22 |
Llc «Anabion» |
Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta
|
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
KR20240095539A
(ko)
|
2021-10-08 |
2024-06-25 |
디노 테라퓨틱스, 인코포레이티드 |
캡시드 변이체 및 이의 사용 방법
|
|
US20230338581A1
(en)
|
2021-10-11 |
2023-10-26 |
Sparingvision |
G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
|
|
US20250025574A1
(en)
|
2021-10-28 |
2025-01-23 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
EP4426716A1
(en)
|
2021-11-02 |
2024-09-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2023108507A1
(en)
*
|
2021-12-15 |
2023-06-22 |
National Institute Of Biological Sciences, Beijing |
Recombinant aav vectors and use thereof
|
|
US20250137011A1
(en)
|
2022-02-02 |
2025-05-01 |
Adverum Biotechnologies, Inc. |
Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
|
|
WO2023158990A1
(en)
|
2022-02-16 |
2023-08-24 |
Adverum Biotechnologies, Inc. |
Method of reducing cst fluctuation in neovascular amd by a recombinant adeno-associated virus
|
|
AU2023220219A1
(en)
*
|
2022-02-17 |
2024-09-05 |
Skyline Therapeutics Limited |
Recombinant adeno-associated virus with modified aav capsid polypeptides
|
|
WO2023178053A1
(en)
|
2022-03-13 |
2023-09-21 |
Regenxbio Inc. |
Modified muscle-specific promoters
|
|
US20250213727A1
(en)
|
2022-03-25 |
2025-07-03 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
US20250213722A1
(en)
*
|
2022-03-30 |
2025-07-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Adeno-associated virus vectors for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells
|
|
IL316014A
(en)
*
|
2022-03-30 |
2024-11-01 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Adeno-associated virus vectors for delivering nucleic acids to retinal cells
|
|
EP4499847A4
(en)
*
|
2022-03-30 |
2026-03-25 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Adeno-associated viral vectors for the delivery of nucleic acids across retinal regions
|
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
|
US20260034243A1
(en)
|
2022-04-06 |
2026-02-05 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene for suprachoroidal administration
|
|
WO2023201207A1
(en)
|
2022-04-11 |
2023-10-19 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
CN116925192B
(zh)
*
|
2022-04-12 |
2025-04-29 |
合肥星眸生物科技有限公司 |
一种融合型腺相关病毒及其应用
|
|
US20250249127A1
(en)
|
2022-04-14 |
2025-08-07 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
CN116970648A
(zh)
*
|
2022-04-24 |
2023-10-31 |
上海朗昇生物科技有限公司 |
新型aav衣壳改造株及其用途
|
|
US20260034246A1
(en)
|
2022-05-03 |
2026-02-05 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
|
JP2025519378A
(ja)
|
2022-06-07 |
2025-06-26 |
アドヴェラム バイオテクノロジーズ， インコーポレイテッド |
視覚回復のためのメラノプシンバリアント
|
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
EP4568710A1
(en)
|
2022-08-11 |
2025-06-18 |
Institute Of Molecular And Clinical Ophthalmology Basel (Iob) |
Human cone photoreceptor optogenetic constructs
|
|
US20260055144A1
(en)
|
2022-08-24 |
2026-02-26 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
IL319873A
(en)
|
2022-09-30 |
2025-05-01 |
Regenxbio Inc |
Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB
|
|
EP4601710A2
(en)
|
2022-10-11 |
2025-08-20 |
RegenxBio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
IL320351A
(en)
|
2022-10-20 |
2025-06-01 |
Sparingvision |
Compositions and methods for treating retinal degenerative disorders
|
|
EP4357359A1
(en)
|
2022-10-20 |
2024-04-24 |
Sparingvision |
G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
|
|
CN120112547A
(zh)
|
2022-11-16 |
2025-06-06 |
瑞泽恩制药公司 |
包含膜结合il-12和蛋白酶可裂解接头的嵌合蛋白
|
|
EP4646478A1
(en)
|
2023-01-06 |
2025-11-12 |
Institut National de la Santé et de la Recherche Médicale |
Intravenous administration of antisense oligonucleotides for the treatment of pain
|
|
CN118359687A
(zh)
*
|
2023-01-18 |
2024-07-19 |
上海朗昇生物科技有限公司 |
一种新衣壳蛋白变体以及其用途
|
|
AU2024214634A1
(en)
|
2023-02-02 |
2025-06-26 |
Quethera Limited |
Recombinant adeno-associated virus vector
|
|
WO2024191778A1
(en)
|
2023-03-10 |
2024-09-19 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
EP4680741A2
(en)
|
2023-03-15 |
2026-01-21 |
RegenxBio Inc. |
Exon skipping gene therapy constructs, vectors and uses thereof
|
|
EP4689184A1
(en)
|
2023-04-05 |
2026-02-11 |
Adverum Biotechnologies, Inc. |
Immune landscape signatures for ocular inflammation
|
|
WO2024211780A1
(en)
|
2023-04-07 |
2024-10-10 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024215655A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Cardioprotective bag3 therapies
|
|
WO2024215653A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Guide rnas, vectors, and virions for targeting mutations in the pln gene
|
|
WO2024216244A2
(en)
|
2023-04-13 |
2024-10-17 |
Regenxbio Inc. |
Targeting aav capsids, methods of manufacturing and using same
|
|
EP4705484A1
(en)
*
|
2023-05-03 |
2026-03-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
TW202444917A
(zh)
*
|
2023-05-04 |
2024-11-16 |
美商航海家醫療公司 |
Ａａｖ衣殼變異體及其用途
|
|
WO2024233529A2
(en)
|
2023-05-07 |
2024-11-14 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024238853A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
WO2024238859A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized c5 inhibitor agents and administration thereof
|
|
WO2024238867A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and administration thereof
|
|
AU2024276934A1
(en)
*
|
2023-05-23 |
2025-12-18 |
Innovec Biotherapeutics |
Adeno-associated virus capsid protein, adeno-associated virus containing same, vector and use thereof
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
KR20260039752A
(ko)
|
2023-07-13 |
2026-03-20 |
크리야 테라퓨틱스, 인크. |
보체 경로 억제제 융합체 및 그의 사용 방법
|
|
CN117230117A
(zh)
*
|
2023-08-04 |
2023-12-15 |
中国科学院深圳先进技术研究院 |
重组腺相关病毒包装质粒、突变体及其制备方法和应用
|
|
TW202508610A
(zh)
|
2023-08-23 |
2025-03-01 |
大陸商上海瑞宏迪醫藥有限公司 |
醫藥組成物及其用途
|
|
AU2024332181A1
(en)
|
2023-08-31 |
2026-02-12 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
CN117143203B
(zh)
*
|
2023-09-06 |
2026-03-03 |
广州译码基因科技有限公司 |
可提高aav病毒全眼感染能力的衣壳蛋白突变体及其应用
|
|
WO2025075963A1
(en)
|
2023-10-02 |
2025-04-10 |
Regenxbio Inc. |
Methods and formulations for treating mucopolysaccharidosis ii-associated hearing loss with recombinant human iduronate-2-sulfatase
|
|
WO2025090962A1
(en)
|
2023-10-25 |
2025-05-01 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
CN117247434B
(zh)
*
|
2023-11-10 |
2024-02-02 |
上海朗昇生物科技有限公司 |
衣壳修饰型病毒载体及其制备和用途
|
|
WO2025106374A1
(en)
|
2023-11-13 |
2025-05-22 |
Juno Therapeutics, Inc. |
Aav production method
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
WO2025129085A1
(en)
|
2023-12-15 |
2025-06-19 |
Port Therapeutics, Inc. |
Use of thermal bioswitches in aav-based gene therapy
|
|
CN119080889B
(zh)
*
|
2024-09-18 |
2025-06-24 |
广州译码基因科技有限公司 |
提高aav对眼组织感染能力的衣壳蛋白突变体及应用
|
|
TW202545971A
(zh)
|
2024-02-08 |
2025-12-01 |
美商戴諾治療公司 |
殼體多肽及其使用方法
|
|
WO2025217214A2
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
TW202548025A
(zh)
*
|
2024-04-08 |
2025-12-16 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
|
WO2025214404A1
(en)
|
2024-04-10 |
2025-10-16 |
Skyline Therapeutics (Shanghai) Co., Ltd. |
Optogenetic modulation for vision restoration
|
|
WO2025214408A1
(en)
|
2024-04-10 |
2025-10-16 |
Skyline Therapeutics (Shanghai) Co., Ltd. |
Optogenetic modulation for vision restoration
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|
|
WO2026006341A1
(en)
|
2024-06-24 |
2026-01-02 |
Regenxbio Inc. |
Microdystrophin gene therapy administration for treatment of dystrophinopathies
|
|
WO2026019885A1
(en)
|
2024-07-16 |
2026-01-22 |
Adverum Biotechnologies, Inc. |
Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
|
|
WO2026064442A2
(en)
|
2024-09-18 |
2026-03-26 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2026080515A2
(en)
|
2024-10-08 |
2026-04-16 |
Regeneron Pharmaceuticals, Inc. |
Crispr sam biosensor cells and cell lines and methods of use thereof
|
|
CN118955654B
(zh)
*
|
2024-10-15 |
2025-05-16 |
朗信启昇(苏州)生物制药有限公司 |
具有变异衣壳的腺相关病毒病毒体及其用途
|